AstraZeneca and Wivi Vision Receive the Bioèxit Prize from CataloniaBio

Awards to the biomedicine and health sector in Catalonia. The British pharmaceutical company AstraZeneca and the Spanish company specialized in the evaluation and treatment of visual dysfunctions Wivi Vision have been awarded this March 11th with the Bioèxit Prize during the celebration of the Nit, the annual event organized by CataloniaBio&HealthTech, an association of the health sector. biomedicine and health in Catalonia.

On this occasion, the award, collected by AstraZeneca’s director of corporate affairs and market access, Marta Moreno, recognizes how significant it has been for the sector and for the city that the pharmaceutical company located its global hub in Barcelona to accelerate the arrival of the new generation of treatments in the five therapeutic areas in which it works: oncology, rare diseases, cardiovascular, renal and metabolism, respiratory and immunology, and vaccines and immunotherapies.

Wivin Vision, for its part, stands out for its business achievements in the last year. The company has developed a system that combines artificial intelligence and big data to provide a complete visual cognitive evaluation and training of visual dysfunctions through 3D video games. The executive director and co-founder of the company, Eva García Ramos, was in charge of collecting the award.

Read more about the award received by AstraZeneca and Wivi Vision and find the most important financial news of the day with our companion app Born2Invest.

AstraZeneca and Wivi Vision have achieved recognition from the biomedicine and health sector in Catalonia

The meeting during which AstraZeneca was awarded, was held at the AXA Auditorium in Barcelona, ​​and brought together more than three hundred attendees including Catalan and Spanish government authorities, entrepreneurs, executives, researchers, partners of the organizing entity and prominent figures in the sector.

It has also had the interventions of the general director of Industrial Strategy and SMEs of the Ministry of Industry, Jordi García, the professor of the University of Lleida (UdL), the International University of Catalonia (UIC) and the Pompeu Fabra University (UPF ), Marta Trapero; the first vice president of the organizing entity, Joan Puig; and the Minister of Health, Manel Balcells.

CataloniaBio was created in March 2006 with the aim of grouping Catalan companies in the field of biotechnology and health sciences under the same umbrella. The merger with HealthTech in 2018 boosted the platform to currently exceed 225 associates . CataloniaBio&HealthTech has played a key role in positioning Barcelona and Catalonia as the second best European location for investment in biotechnology and health.

__

(Featured image by jarmoluk via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us